- Companies
- TytoCare
TytoCare Valuation, Funding & Investors
TytoCare is valued at $400M as of March 2021.
Last TytoCare valuation
$400M
Series D · Mar 2021
Last TytoCare funding round
$25M
Undisclosed stage · Jul 2026
Cumulative funding TytoCare raised
$229M
across 8 funding rounds
Key investors in TytoCare
OrbiMed
Insight Partners
Qualcomm Ventures
Fosun International
LionBird
OTV
About TytoCare
TytoCare is a Tel Aviv-headquartered digital health company offering remote examination devices and telehealth platforms. TytoHome enables consumer self-exams of heart, lungs, skin, throat, ears, and temperature, while TytoPro supports clinicians and TytoClinic serves clinics. The system includes AI-guided tools, video consultations, and cloud analytics, used by over 1,000 healthcare organizations globally.
Founded
2011
HQ
Website
Status
Privately held
Customer focus
B2C & B2B
Revenue model
Product sales
Valuation
$400M (Mar 2021)
TytoCare Valuation
TytoCare is currently valued at $400M, based on its Series D in March 2021.
The $50M round was led by Insight Partners, with participation from Qualcomm Ventures, Tiger Global, Shenzhen Capital Group, Qumra Capital and OTV.
TytoCare valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Mar 2021 | Series D | $400M |
TytoCare Funding History
TytoCare has raised a total of $229M across 8 funding rounds.
TytoCare's first fundraising round was a $7M Series A in March 2014. The most recent completed round was a $25M undisclosed-stage round in July 2026.
TytoCare funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jul 2026 | Undisclosed stage | Insight Partners (lead); Qualcomm Ventures; Healthcare of Ontario Pension Plan (HOOPP); OrbiMed; Qumra Capital; OTV | $25M | - | - |
| Aug 2023 | Series E | Insight Partners (lead); MemorialCare Innovation Fund; Healthcare of Ontario Pension Plan (HOOPP); Clal Biotechnology | $49M | - | TytoCare is a virtual care company providing an all-in-one modular device and telehealth platform for AI-powered remote medical examinations, enabling health plans and providers to deliver clinic-quality primary care from home via its Home Smart Clinic solution. The company announced a $49 million growth funding round on August 3, 2023, led by existing investor Insight Partners, with participation from new investors MemorialCare Innovation Fund, Healthcare of Ontario Pension Plan (HOOPP), and Clal Biotechnology, bringing total funding to $205 million. This round follows previous investments, including a $50 million Series D extension in March 2021 also led by Insight Partners. The funding will support development of novel AI uses in diagnostic support and remote exam assistance, particularly advancing the Home Smart Clinic’s longitudinal care capabilities for managing chronic conditions beyond acute visits. TytoCare recently received FDA clearance for its AI-powered Tyto Insights for Wheeze Detection software, which evaluates lung sounds via its stethoscope to identify wheezing in adults and children aged 2 and older, with a European CE Mark obtained the prior year. The platform emphasizes high engagement, with utilization rates five times higher than traditional telehealth, average total cost of care reduction of five percent, ED visit diversion of 10.8 percent, and NPS of 83. TytoCare continues to focus on scaling AI-enhanced virtual care solutions amid growing telehealth adoption. |
| Mar 2021 | Series D | Insight Partners (lead); Qualcomm Ventures; Tiger Global; Shenzhen Capital Group; Qumra Capital; OTV | $50M | $400M | TytoCare is a telehealth company providing an all-in-one modular device and platform for AI-powered, on-demand remote medical examinations, enabling clinic-quality exams from home. TytoCare emphasized its differentiation through end-to-end solutions beyond video visits, supporting remote monitoring, diagnosis, and treatment. The Series D extension round on March 4, 2021, raised $50 million led by Insight Partners, with participation from new investors Tiger Global Management and Qumra Capital, plus existing investors Qualcomm Ventures, Olive Tree Ventures (OTV), and Shenzhen Capital Group. This followed a $50 million Series D in April 2020, totaling $100 million raised in 10 months and $155 million overall. Funds were allocated to expand the full-stack telehealth platform in the US, Europe, and Asia, penetrate the global healthcare payer market, and develop advanced AI-based diagnostic tools and services. CEO Dedi Gilad highlighted strong pre-COVID growth accelerated by the pandemic, boosting telehealth adoption. Insight Partners' Jeff Horing praised TytoCare's leadership in virtual care innovation. |
| Apr 2020 | Series D | Insight Partners (lead); OTV (lead); Qualcomm Ventures (lead); Echo Health Ventures; OrbiMed; Teuza a Fairchild; Qure | $50M | - | - |
| Jan 2019 | Series C | Ping An Global Voyager (lead); Sanford Health; ITOCHU; Shenzhen Capital Group | $9M | - | TytoCare is an Israeli telehealth company providing devices and platforms for remote medical examinations, including TytoHome for patients, TytoPro for professionals, and TytoClinic for point-of-care testing, along with telehealth software, analytics, and AI guidance. On January 16, 2019, TytoCare closed $9 million in additional Series C funding from strategic investors Sanford Health, Itochu, and Shenzhen Capital Group, extending the 2018 round led by Ping An Global Voyager Fund and bringing the total Series C to $33.5 million. The funds support growth initiatives, global expansion into the US, Japan, China, and Europe, and partnerships to enhance remote healthcare access in rural and aging populations. TytoCare had gained traction post-FDA clearance in 2017 and CE Mark in 2018 with major US health systems and telehealth partners. The company targets chronic conditions and underserved areas through its at-home exam solutions replicating a doctor's office. |
| Jan 2018 | Series C | Ping An (lead); MTIP AG; LionBird; ITOCHU; Walgreens; Fosun International; OrbiMed; Cambia Health Solutions | $27M | - | TytoCare is an Israeli telehealth company founded in 2012 that developed connected medical devices to enable remote home examinations and telehealth services. The company's product portfolio includes TytoHome for patients, TytoPro for professionals, and TytoClinic for remote point-of-care testing, featuring breakthrough technology such as FDA-cleared digital stethoscopes for conducting comprehensive remote medical exams. In January 2018, TytoCare closed a $25 million Series B funding round led by Ping An Global Voyager Fund, with participation from new and existing investors including Cambia Health Solutions, Walgreens, OrbiMed, Fosun Pharma, LionBird, and new investor Qure (Israel's first digital health-focused fund established with Johns Hopkins University). As part of the oversubscribed round, the company had the option to expand funding to $28 million. The funding was announced shortly after the company achieved FDA clearance in late 2016 and product launch in the U.S. in early 2017, with the company having gained significant traction among major U.S. health systems, telehealth companies, large private practices, and employers. The capital was designated to support expansion in the U.S. market, enhance product offerings and smart data analytics capabilities, and establish a strategic partnership with Ping An to penetrate the Chinese market through integration with Ping An's Good Doctor mobile app. By the time of this round, TytoCare had raised more than $45 million cumulatively; an additional $9 million expansion of the Series C round followed in January 2019, bringing that tranche to $33.5 million total and funded by Ping An Global Voyager Fund along with new investors Sanford Health, Itochu, and Shenzhen Capital Group. |
| Jul 2015 | Series B | Cambia Health Solutions (lead); Teuza a Fairchild (lead); LionBird; Walgreens; Fosun International; OrbiMed | $12M | - | TytoCare, an Israeli medical device company founded by Dedi Gilad and Ofer Tzadik, raised $11 million in a funding round on July 15, 2015, led by a major American strategic investment firm and Teuza Venture Capital. The round brought the company's total funding to $18.5 million at that time. TytoCare's platform enables parents to conduct basic medical examinations at home and send results to doctors. |
| Mar 2014 | Series A | LionBird (lead); OrbiMed (lead); Walgreens; Fosun International | $7M | - | TytoCare raised $7 million in its Series A round in March 2014, led by LionBird and OrbiMed. The investors included Fosun International, LionBird, OrbiMed, and Walgreens. The funding aimed to expand the team and enhance the platform's capabilities. TytoCare, founded in 2011, develops a telehealth platform enabling remote medical examinations of the lungs, heart, throat, ears, abdomen, and body temperature. The modular device integrates with EHRs and supports both live exams and asynchronous data forwarding. |
Who has invested in TytoCare?
22 investors have backed TytoCare across its funding rounds, including OrbiMed, Insight Partners, Qualcomm Ventures, Fosun International, LionBird and OTV.
Lead investors include Insight Partners, OTV, Qualcomm Ventures, Ping An Global Voyager, Ping An and 4 other investors.
TytoCare Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Lead | Mar 2014 | ||
| 4 | Lead | Apr 2020 | ||
| 3 | Lead | Apr 2020 | ||
| 3 | Lead | Mar 2014 | ||
| 3 | Participant | Mar 2014 | ||
| 3 | Participant | Mar 2014 | ||
| 3 | Lead | Apr 2020 | ||
| 2 | Participant | Jan 2018 | ||
| 2 | Participant | Aug 2023 | ||
| 2 | Participant | Jan 2019 | ||
| 2 | Participant | Mar 2021 | ||
| 2 | Lead | Jul 2015 | ||
| 2 | Lead | Jul 2015 | ||
This data is available for Pro users. Sign up to see all 22 TytoCare investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialTytoCare Competitors
TytoCare competitors include listed companies like Nanjing Medlander Medical and Orchestra BioMed, and private ones like Eko Health, BioIntelliSense, InnerMedical and Svision.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $395M | - | ||
| Private | - | - | $350M | - | ||
| Publicly listed | $64M | $20M | $418M | - | ||
| Private | - | - | $363M | - | ||
| Private | - | - | $348M | - | ||
| Publicly listed | $33M | ($51M) | $347M | 28.8x |
TytoCare Public Comps
TytoCare is still privately-owned, but its public comps include CellaVision, Myriad Genetics, Nanjing Medlander Medical, ClearPoint Neuro, Carlsmed, Carvolix, NIOX Group, Shoulder Innovations, TaiDoc Technology and Sofwave Medical.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $77M | $24M | 5.0x | 4.8x | 16.2x | 15.9x | |||
| $825M | ($332M) | 0.6x | 0.6x | (1.5x) | (16.8x) | |||
| $64M | $20M | 4.9x | - | 15.8x | - | |||
| $37M | ($22M) | 12.3x | 10.0x | (20.6x) | (20.7x) | |||
| $51M | ($31M) | 7.0x | 5.1x | (11.5x) | (10.2x) | |||
| $5M | ($14M) | 93.1x | 246.4x | (32.0x) | (15.6x) | |||
| $65M | $20M | 5.3x | 5.2x | 17.4x | 15.1x | |||
| $47M | ($37M) | 6.1x | 4.6x | (7.7x) | (8.5x) | |||
This data is available for Pro users. Sign up to see all TytoCare competitors and their valuation data. Start Free Trial | ||||||||
Common questions about TytoCare
| When was TytoCare founded? | TytoCare was founded in 2011. |
| Where is TytoCare headquartered? | TytoCare is headquartered in New York City, NY, United States. |
| Is TytoCare publicly listed? | No, TytoCare is a private, VC-backed company. |
| What is TytoCare's valuation? | TytoCare was last valued at $400M in its Series D in March 2021. |
| How much funding has TytoCare raised? | TytoCare has raised $229M across 8 funding rounds. |
| What was TytoCare's last funding round? | TytoCare's last funding round was a $25M undisclosed-stage round in July 2026, led by Insight Partners. |
| Who are TytoCare's investors? | TytoCare's investors include OrbiMed, Insight Partners, Qualcomm Ventures, LionBird, Walgreens, Fosun International, OTV, ITOCHU, Healthcare of Ontario Pension Plan (HOOPP), Shenzhen Capital Group and 12 others. |
| Which companies are comparable to TytoCare? | Companies comparable to TytoCare include Eko Health, BioIntelliSense, Nanjing Medlander Medical, InnerMedical, Svision and Orchestra BioMed. |
See companies similar to TytoCare
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




